1. Юкина М.Ю., Трошина Е.А., Платонова Н.М., Бельцевич Д.Г. Надпочечниковая недостаточность. В кн.: Трошина Е.А. Сборник методических рекомендаций (в помощь практическому врачу) – Тверь: Триада, 2017. – С. 149-192. 2. Ramos-Prol A., Rubio-Almanza M., Campos-Alborg V., Febrer-Bosch I., Merino-Torres J.F. Chronic autoimmune urticaria as a possible non endocrine manifestation of autoimmune polyglandular syndrome type II. Endocrinol Nutr. 2011; №58 (9):497-505. 3. Anaya J.M. The diagnosis and clinical significance of polyautoimmunity. Autoimmunity Reviews. 2014; №13 (4–5):423-426. 4. Cojocaru M., Cojocaru I.M., Silosi I. Multiple autoimmune syndrome. Maedica (Buchar). 2010; №5 (2):132–134. 5. Husebye E.S., Perheentupa J., Rautemaa R., Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009; №265:514–29. 52 6. Martín-Campagne E., Ballester-Herrera M.J., Palomo-Atance E., Sánchez-Ruiz P., GiraltMuiña P. Hyponatremic rhabdomyolysis in Addison’s disease in a child with autoimmune polyglandular syndrome type 2. Endocrinol Nutr. 2015; №62:511-512. 7. Al-sharefi A., Khan U., Tarigopula G., Peter P., Kamaruddin S., Partha P. Late Onset Diabetes of Adults (LADA) Masked By Coexistent Adrenal Failure in the Context of Autoimmune Polyglandular Syndrome 2. Journal of Diabetes, Metabolic Disorders & Control. 2016; №3 (3):00070. 8. Betterle C., Garelli S., Coco G., Burra P. A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). Auto Immun Highlights. 2014; №5 (1):27-31. 9. Naletto L., Frigo A., Ceccato F., Sabbadin C., Scarpa R., Presotto F., Dalla Costa M., Faggian D., Plebani M., Censi S., Manso J., Furmaniak J., Chen S., Rees Smith B., Masiero S., Pigliaru F., Boscaro M., Scaroni C., Betterle C. The natural history of autoimmune Addison's disease from the detection of autoantibodies to development of the disease: a long follow-up study on 143 patients. Eur J Endocrinol. 2019. pii: EJE-18-0313.R3. 10. Gherbon A. Prevalence of polyglandular autoimmune syndrome type iii in a group of adults with thyroid diseases and diabetes mellitus. 1st Annual International Interdisciplinary Conference, AIIC 2013, 24-26 April, Azores, Portugal. 11. Husebye E.S., Anderson M.S., Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018; №378 (12):1132–1141. 12. Bornstein S.R. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009; №360:2328–2339. 13. Rashidi A., Fisher S.I. Primary adrenal lymphoma: a systematic review. Ann Hematol. 2013; №92 (12):1583-93. 14. Laurent C., Casasnovas O., Martin L., Chauchet A., Ghesquieres H., Aussedat G., Fornecker L., Bologna S., Borot S., Laurent K., Bouillet B., Verges B., Petit J-M. Primary Adrenal Lymphoma: presentation, management and prognosis. QJM. 2017; №110 (2):103- 109. 15. Gonzalez-Rodriguez E., Rodriguez-Abreu D., Spanish Group for Cancer I-B. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016; №21 (7):804-816. 16. Colombo C, De Leo S, Di Stefano M, Vannucchi G, Persani L, Fugazzola L. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. J Clin Endocrinol Metab. 2019; №104 (3):779-784. 53 17. Allolio B. Extensive expertise in endocrinology: adrenal crisis. Eur J Endocrinol. 2015; №172 (3):R115–R124. 18. Фадеев В.В., Мельниченко Г.А. Надпочечниковая недостаточность (клиника, диагностика, лечение). Методические рекомендации для врачей. Москва: Медпрактика-М; 2003. 19. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. 3-е изд., перераб. и доп. – Москва: Литтерра; 2015. 20. Chakera A.J., Vaidya B. Addison disease in adults: diagnosis and management. Am J Med. 2010; №123:409–413. 21. Erichsen M.M., Løvås K., Skinningsrud B., Wolff A.B., Undlien D.E., Svartberg J., Fougner K.J., Berg T.J., Bollerslev J., Mella B., Carlson J.A., Erlich H., Husebye E.S. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009; №94 (12):4882-90. 22. Charmandari E., Nicolaides N.C., Chrousos G.P. Adrenal insufficiency. Lancet. 2014; №383 (9935):2152-2167. 23. Meyer G., Neumann K., Badenhoop K., Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008–2012. Eur J Endocrinol. 2014; №170:367–373. 24. Quinkler M., Beuschlein F., Hahner S., Meyer G., Schöfl C., Stalla G.K. Adrenal cortical insufficiency—a life threatening illness with multiple etiologies. Dtsch Arztebl Int 2013; №110 (51–52): 882–8. 25. Bleicken B., Hahner S., Ventz M., Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010; №339:525–531. 26. Bornstein S.R., Allolio B., Arlt W., Barthel A., Don-Wauchope A., Hammer G.D., Husebye E.S., Merke D.P., Murad M.H., Stratakis C.A., Torpy D.J. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; №101 (2):364-89. 27. Oelkers W., Diederich S., Bähr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab. 1992; №75:259–264. 28. Oelkers W. Adrenal insufficiency. NEngl J Med. 1996; №335:1206–1212. 29. Jones D.A., Miras A., Tringham J.R. Addison’s disease: a diagnostic challenge. Br J Hosp Med (Lond). 2008; №69:M192–M195. 54 30. Oelkers W., Boelke T., Bähr V. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1–39) or human corticotropin-releasing hormone in man. J Clin Endocrinol Metab. 1988; №66:181–186. 31. Lee M.K., Vasikaran S., Doery J.C., Wijeratne N., Prentice D. Cortisol:ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgrad Med J. 2013; №89:617–620. 32. Saenger P., Levine L.S., Irvine W.J., Gottesdiener K., Rauh W., Sonino N., Chow D., New M.I. Progressive adrenal failure in polyglandular autoimmune disease. J Clin Endocrinol Metab.1982; №54:863–867. 33. Coco G., Dal Pra C., Presotto F., Albergoni M.P., Canova C., Pedini B., Zanchetta R., Chen S., Furmaniak J., Rees Smith B., Mantero F., Betterle C. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab. 2006; №91:1637–1645. 34. Gagliardi L., Ho J.T., Torpy D.J. Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol. 2010; №316:24–34. 35. Orphanet [Internet]: Corticosteroid-binding globulin deficiency. URL: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=199247. 36. Torpy D.J., Bachmann A.W., Grice J.E., Fitzgerald S.P., Phillips P.J., Whitworth J.A., Jackson R.V. Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab. 2001; №86 (8):3692-700. 37. De Bellis A., Bizzarro A., Rossi R., Paglionico V.A., Criscuolo T., Lombardi G., Bellastella A. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab. 1993; №76:1002–1007. 38. Betterle C., Scalici C., Presotto F., Pedini B., Moro L., Rigon F., Mantero F. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol. 1988; №117:467–475. 39. Le Roux C.W., Meeran K., Alaghband-Zadeh J. Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment? Ann Clin Biochem. 2002; №39 (2):148- 50. 40. El-Farhan N., Pickett A., Ducroq D., Bailey C., Mitchem K., Morgan N., Armston A., Jones L., Evans C., Rees D.A. Method-specific serum cortisol responses to the adrenocorticotrophin test: comparison of gas chromatography-mass spectrometry and five automated immunoassays. Clin Endocrinol (Oxf). 2013; №78:673–680. 55 41. Jenkins D., Forsham P.H., Laidlaw J.C., Reddy W.J., Thorn G.W. Use of ACTH in the diagnosis of adrenal cortical insufficiency. Am J Med. 1955; №18:3–14. 42. Hägg E., Asplund K., Lithner F. Value of basal plasma cortisol assays in the assessment of pituitary-adrenal insufficiency. Clin Endocrinol (Oxf). 1987; №26:221–226. 43. Baker P.R., Baschal E.E., Fain P.R., Triolo T.M., Nanduri P., Siebert J.C., Armstrong T.K., Babu S.R., Rewers M.J., Gottlieb P.A., Barker J.M., Eisenbarth G.S. Haplotype analysis discriminates genetic risk for DR3-associated endocrine autoimmunity and helps define extreme risk for Addison’s disease. J Clin Endocrinol Metab. 2010; №95:E263–E270. 44. Van Rijn J.L., Van Landeghem B.A., Haima P., Goldschmidt H.M. Evaluation of ACTH immunoradiometric assays. Clin Biochem. 1996; №29:93–95. 45. Pecori Giraldi F., Saccani A., Cavagnini F. Assessment of ACTH assay variability: a multicenter study. Eur J Endocrinol. 2011; №164:505–512. 46. Erturk E., Jaffe C.A., Barkan A.L. Evaluation of the integrity of the hypothalamicpituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab. 1998; №83:2350–2354. 47. Rehan M., Raizman J.E., Cavalier E., Don-Wauchope A.C., Holmes D.T. Laboratory challenges in primary aldosteronism screening and diagnosis. Clin Biochem. 2015; №48:377–387. 48. Schmidt I.L., Lahner H., Mann K., Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003; №88:4193–4198. 49. Nelson J.C., Tindall D.J.Jr. A comparison of the adrenal responses to hypoglycemia, metyrapone and ACTH. Am J Med Sci. 1978; №275 (2):165-72. 50. Grinspoon S.K., Biller B.M. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994; №79:923–931. 51. Gundgurthi A., Garg M.K., Dutta M.K., Pakhetra R. Intramuscular ACTH stimulation test for assessment of adrenal function. J Assoc Physicians India. 2013; №61:320–324. 52. Dhillo W.S., Kong W.M., Le Roux C.W., Alaghband-Zadeh J., Jones J., Carter G., Mendoza N., Meeran K., O'Shea D. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic–pituitary–adrenal axis. Eur J Endocrinol. 2002; №146:231–235. 53. Mueller U.W., Potter J. Binding of cortisol to human albumin and serum: the effect of protein concentration. Biochem Pharmacol.1981; №30:727–733. 56 54. Klose M., Lange M., Rasmussen A.K., Skakkebaek N.E., Hilsted L., Haug E., Andersen M., Feldt-Rasmussen U. Factors influencing the adrenocorticotropin test: role of contemporary cortisol assays, body composition, and oral contraceptive agents. J Clin Endocrinol Metab. 2007; №92:1326–1333. 55. Vincent R.P., Etogo-Asse F.E., Dew T., Bernal W., Alaghband-Zadeh J., le Roux C.W. Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adrenal axis reserve in patients with liver impairment. Ann Clin Biochem. 2009; №46:505–507. 56. le Roux C.W., Chapman G.A., Kong W.M., Dhillo W.S., Jones J., Alaghband-Zadeh J. Free cortisol index is better than serum total cortisol in determining hypothalamicpituitary-adrenal status in patientsundergoing surgery. J Clin Endocrinol Metab. 2003; №88:2045–2048. 57. Hamrahian A.H., Oseni T.S., Arafah B.M. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004; №350:1629–1638. 58. Suri D., Moran J., Hibbard J.U., Kasza K., Weiss R.E. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006; №91:3866–3872. 59. Lebbe M., Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf). 2013; №78:497–502. 60. Reimondo G., Bovio S., Allasino B., Terzolo A. Secondary hypoadrenalism. Pituitary. 2008; №11:147-54. 61. de Miguel Novoa P., Vela E.T., García N.P., Rodríguez M.M., Guerras I.S., Martínez de Salinas Santamaría Mde L., Masó A.A., Área de Conocimiento del Grupo de Neuroendocrino de la SEEN (Grupo Insuficiencia Adrenal). Guidelines for the diagnosis and treatment of adrenal insufficiency in the adult. Endocrinol Nutr. 2014; №61 Suppl 1:1- 35. 62. Berg C., Meinel T., Lahner H., Yuece A., Mann K., Petersenn S. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol. 2010; №162(3):477-82. 63. Karaca Z., Lale A., Tanriverdi F., Kula M., Unluhizarci K., Kelestimur F. The comparison of low and standard dose ACTH and glucagon stimulation test in the evaluation of hypothalamo-pituitary-adrenal axis in healthy adults. Pituitary. 2011; №14:134-40. 64. Snow K., Jiang N.S., Kao P.C., Scheithauer B.W. Biochemical evaluation of adrenal dysfunction: the laboratory perspective. Mayo Clin Proc. 1992; №67 (11):1055-65. 57 65. Horn M.A., Erichsen M.M., Wolff A.S., Månsson J.E., Husebye E.S., Tallaksen C.M., Skjeldal O.H. Screening for X-linked adrenoleukodystrophy among adult men with Addison’s disease. Clin Endocrinol (Oxf). 2013; №79:316–320. 66. Vita JA, Silverberg SJ, Goland RS, Austin JH, Knowlton AI. Clinical clues to the cause of Addison’s disease. Am J Med. 1985; №78:461–466. 67. Knutsson U., Dahlgren J., Marcus C., Rosberg S., Brönnegård M., Stierna P., AlbertssonWikland K. Circadian cortisol rhythms in healthy boys and girls: relationship with age, growth, body composition, and pubertal development. J Clin Endocrinol Metab. 1997; №82:536–540. 68. Linder B.L., Esteban N.V., Yergey A.L., Winterer J.C., Loriaux D.L., Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr. 1990; №117:892–896. 69. Esteban N.V., Loughlin T., Yergey A.L., Zawadzki J.K., Booth J.D., Winterer J.C., Loriaux D.L. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991; №72:39–45. 70. Kerrigan J.R., Veldhuis J.D., Leyo S.A., Iranmanesh A., Rogol A.D. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993; №76:1505–1510. 71. Purnell J.Q., Brandon D.D., Isabelle L.M., Loriaux D.L., Samuels M.H. Association of 24- hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab. 2004; №89:281–287. 72. Czock D., Keller F., Rasche F.M., Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005; №44:61–98. 73. Plat L., Leproult R., L’Hermite-Baleriaux M., Fery F., Mockel J., Polonsky K.S., Van Cauter E. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab. 1999; №84:3082–3092. 74. Simon N. Castinetti F., Ouliac F., Lesavre N., Brue T., Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet. 2010; №49:455–463. 75. Allolio B., Winkelmann W., Fricke U., Heesen D., Kaulen D. Cortisol plasma concentration in patients with primary adrenal cortex insufficiency during substitution therapy with cortisone acetate [in German]. Verh Dtsch Ges Inn Med. 1978; №84:1456– 1458. 58 76. Peacey S.R., Guo C.Y., Robinson A.M., Price A, Giles M.A., Eastell R., Weetman A.P. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf). 1997; №46:255–261. 77. Howlett T.A. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997; №46:263–268. 78. Mah P.M., Jenkins R.C., Rostami-Hodjegan A., Newell-Price J., Doane A., Ibbotson V., Tucker G.T., Ross R.J. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004; №61:367–375. 79. Laureti S., Falorni A., Santeusanio F. Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest. 2003; №26:1071–1075. 80. Barbetta L., Dall’Asta C., Re T., Libè R., Costa E., Ambrosi B. Comparison of different regimens of glucocorticoid replacement therapy in patients with hypoadrenalism. J Endocrinol Invest. 2005; №28:632–637. 81. Ekman B., Bachrach-Lindström M., Lindström T., Wahlberg J., Blomgren J., Arnqvist H.J. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol andACTHprofiles in patients with primary adrenal insufficiency. Clin Endocrinol (Oxf). 2012; №77:18–25. 82. Alonso N., Granada M.L., Lucas A., Salinas I., Reverter J., Oriol A., Sanmarti A. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest. 2004; №27:449–454. 83. Forss M., Batcheller G., Skrtic S., Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord. 2012; №12:8. 84. Fariss B.L., Hane S., Shinsako J., Forsham P.H. Comparison of absorption of cortisone acetate and hydrocortisone hemisuccinate. J Clin Endocrinol Metab. 1978; №47:1137– 1140. 85. Filipsson H., Monson J.P., Koltowska-Häggström M., Mattsson A., Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006; №91:3954–3961. 59 86. Fadeev V.V., Gitel E.P., Mel’nichenko G.A. The diurnal rhythm of adrenocorticotropic hormone secretion in the assessment of the adequacy of replacement therapy in primary chronic adrenal failure. Neurosci Behav Physiol. 2001; №31:237–242. 87. Falorni A., Minarelli V., Morelli S. Therapy of adrenal insufficiency: an update. Endocrine. 2013; №43 (3):514-28. 88. Løvås K., Husebye E.S. Replacement therapy in Addison's disease. Expert Opin Pharmacother. 2003; №4 (12):2145-9. 89. Kiko N., Kalhan A. Comparison of Various Glucocorticoid Replacement Regimens Used in Chronic Adrenal Insufficiency: A Systematic Review. Dubai Diabetes Endocrinol J. 2020; №26:50–68. 90. Debono M., Ross R.J. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012? Clinical Endocrinology. 2013; № 78:659–664. 91. Grossman A., Johannsson G., Quinkler M., Zelissen P. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol. 2013; №169:165-75. 92. Reisch N., Arlt W. Fine tuning for quality of life: 21st century approach to treatment of Addison’s disease. Endocrinol Metab Clin N Am. 2009; №38:407-18. 93. Quinkler M., Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012; №76:21–25. 94. Quinkler M., Ekman B., Marelli C., Uddin S., Zelissen P., Murray R.D., EU-AIR Investigators. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect. 2017; №6 (1):1-8. 95. Bouvattier C., Esterle L., Renoult-Pierre P., de la Perrière A.B., Illouz F., Kerlan V., Pascal-Vigneron V., Drui D. , Christin-Maitre S., Galland F., Brue T., Reznik Y., Schillo F., Pinsard D., Piguel X., Chabrier G., Decoudier B., Emy P., Tauveron I., Raffin-Sanson M.L., Bertherat J., Kuhn J.M., Caron P., Cartigny M., Chabre O., Dewailly D., Morel Y., Touraine P., Tardy-Guidollet V., Young J. Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21- Hydroxylase Deficiency. A French National Survey. J Clin Endocrinol Metab. 2015; №100 (6):2303-13. 96. Williams G.H., Cain J.P., Dluhy R.G., Underwood R.H. Studies of the control of plasma aldosterone concentration in normal man. I. Response to posture, acute and chronic volume depletion, and sodium loading. J Clin Invest. 1972; №51:1731–1742. 97. Miller W.L., Auchus R.J. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011; №32:81–151. 60 98. Oelkers W., L’Age M. Control of mineralocorticoid substitution in Addison’s disease by plasma renin measurement. Klin Wochenschr. 1976; №54:607–612. 99. Flad T.M., Conway J.D., Cunningham S.K., McKenna T.J. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency. Clin Endocrinol (Oxf). 1996; №45:529–534. 100. Methlie P., Husebye E.E., Hustad S., Lien E.A., Løvås K. Grapefruit juice and licorice increase cortisol availability in patients with Addison’s disease. Eur J Endocrinol. 2011; №165:761–769. 101. Keilholz U., Guthrie G.P. Jr. Adverse effect of phenytoin on mineralocorticoid replacement with fludrocortisone in adrenal insufficiency. Am J Med Sci. 1986; №291:280–283. 102. Ross I.L., Bergthorsdottir R., Levitt N., Dave J.A., Schatz D., Marais D., Johannsson G. Cardiovascular risk factors in patients with Addison’s disease: a comparative study of South African and Swedish patients. PLoS One. 2014; №9:e90768. 103. Inder W.J., Meyer C., Hunt P.J. Management of hypertension and heart failure in patients with Addison’s disease. Clin Endocrinol (Oxf). 2015; №82:789–792. 104. Quinkler M., Oelkers W., Remde H., Allolio B. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2015; №29 (1):17-24. 105. Devogelaer J.P., Crabbé J., Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed). 1987; №294(6575):798-800. 106. Jung C., Ho J.T., Torpy D.J., Doogue M., Lewis J.G., Czajko R.J., Inder W.J. A longitudinal study of plasma and urinary cortisol in pregnancy and postpartum. J Clin Endocrinol Metab. 2011; №96:1533–1540. 107. Allolio B., Hoffmann J., Linton E.A., Winkelmann W., Kusche M., Schulte H.M. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasinghormone. Clin Endocrinol (Oxf). 1990; №33:279–289. 108. Zelissen P.M., Croughs R.J., van Rijk P.P., Raymakers J.A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med. 1994; №120:207–210. 109. Bancos I., Hahner S., Tomlinson J., Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015; №3:216–226. 61 110. Hahner S., Loeffler M., Bleicken B., Drechsler C., Milovanovic D., Fassnacht M., Ventz M., Quinkler M., Allolio B. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol. 2010; №162:597– 602. 111. White K., Arlt W. Adrenal crisis in treated Addison’s disease: a predictable but under-managed event. Eur J Endocrinol. 2010; №162:115–120. 112. Hahner S., Spinnler C., Fassnacht M., Burger-Stritt S., Lang K., Milovanovic D., Beuschlein F., Willenberg H.S., Quinkler M., Allolio B. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015; №100:407–416. 113. Reisch N., Willige M., Kohn D., Schwarz H.P., Allolio B., Reincke M., Quinkler M., Hahner S., Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012; №167:35–42. 114. Abdallah M.S., Madi A.F., Rana M.A. The Best Use of Systemic Corticosteroids in the Intensive Care Units, Review. J Steroids Horm Sci. 2015; №6:1. DOI: 10.4172/2157- 7536.1000149. 115. Woodcock T., Barker P., Daniel S., Fletcher S., Wass J.A.H., Tomlinson J.W., Misra U., Dattani M., Arlt W., Vercueil A. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK.Anaesthesia. 2020; №75:654–663. 116. Jung C., Inder W.J. Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust. 2008; №188(7):409-13. 117. Hahner S., Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009; №23:167–179. 118. Meyer G., Hackemann A., Penna-Martinez M., Badenhoop K. What affects the quality of life in autoimmune Addison’s disease? Horm Metab Res. 2013; №45:92–95. 119. Repping-Wuts H.J., Stikkelbroeck N.M., Noordzij A., Kerstens M., Hermus A.R. A glucocorticoid education group meeting: an effective strategy for improving selfmanagement to prevent adrenal crisis. Eur J Endocrinol. 2013; №169:17–22. 120. Chernow B., Alexander H.R., Smallridge R.C., Thompson W.R., Cook D., Beardsley D., Fink M.P., Lake C.R., Fletcher J.R. Hormonal responses to graded surgical stress. Arch Intern Med. 1987; №147:1273–1278. 62 121. Udelsman R., Norton J.A., Jelenich S.E., Goldstein D.S., Linehan W.M., Loriaux D.L., Chrousos G.P. Responses of the hypothalamic-pituitary-adrenal and reninangiotensin axes and the sympathetic system during controlled surgical and anesthetic stress. J Clin Endocrinol Metab. 1987; №64:986–994. 122. Rains P.C., Rampersad N., De Lima J., Murrell D., Kinchington D., Lee J.W., Maguire A.M., Donaghue K.C. Cortisol response to general anaesthesia for medical imaging in children. Clin Endocrinol (Oxf). 2009; №71:834–839. 123. Hsu A.A., von Elten K., ChanD., Flynn T., Walker K., Barnhill J., Naun C., Pedersen A.M., Ponaman M., Fredericks G.J., Crudo D.F., Pinsker J.E. Characterization of the cortisol stress response to sedation and anesthesia in children. J Clin Endocrinol Metab. 2012; №97:E1830–E1835. 124. Taylor L.K., Auchus R.J., Baskin L.S., Miller W.L. Cortisol response to operative stress with anesthesia in healthy children. J Clin Endocrinol Metab. 2013; №98:3687– 3693. 125. Sapolsky R.M., Romero L.M., Munck A.U. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev. 2000; №21:55– 89. 126. Koniaris L.G., Wand G., Wright T.M. TNF mediates a murine model of Addison’s crisis. Shock. 2001; №15:29–34. 127. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg. 1994; №219:416–425. 128. Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 1997; №121:123–129. 129. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness.NEngl J Med. 2013; №368:1477–1488. 130. Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol. 2013; №169:147–154. 131. Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B. Timelines in the management of adrenal crisis - targets, limits and reality. Clin Endocrinol (Oxf). 2015; №82:497–502. 132. Chortis V., Taylor A.E., Schneider P., Tomlinson J.W., Hughes B.A., O'Neil D.M., Libé R., Allolio B., Bertagna X., Bertherat J., Beuschlein F., Fassnacht M., Karavitaki N., Mannelli M., Mantero F., Opocher G., Porfiri E., Quinkler M., Sherlock M., Terzolo M., 63 Nightingale P., Shackleton C.H., Stewart P.M., Hahner S., Arlt W. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013; №98:161–171. 133. Quinkler M., Dahlqvist P., Husebye E.S., Kämpe O. A European Emergency Card for adrenal insufficiency can save lives. Eur J Intern Med. 2015; №26:75–76. 134. Schulz J., Frey K.R., Cooper M.S., Zopf K., Ventz M., Diederich S., Quinkler M. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol. 2016; №174(4):531-8. 135. Falhammar H. Skeletal fragility induced by overtreatment of adrenal insufficiency. Endocrine. 2018; №59 (2):239-241. 136. ErichsenM.M., Løvås K., Fougner K.J., Svartberg J., Hauge E.R., Bollerslev J., Berg J.P., Mella B., Husebye E.S. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol. 2009; №160:233–237. 137. Fichna M., Fichna P., Gryczyn´ska M., Walkowiak J., Zurawek M., Sowiński J. Screening for associated autoimmune disorders in Polish patients with Addison’s disease. Endocrine. 2010; №37:349–360. 138. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison’s disease. J Autoimmun. 1995; №8:121–130. 139. Betterle C., Scarpa R., Garelli S., Morlin L., Lazzarotto F., Presotto F., Coco G., Masiero S., Parolo A., Albergoni M.P., Favero R., Barollo S., Salvà M., Basso D., Chen S., Rees Smith B., Furmaniak J., Mantero F. Addison’s disease: a survey on 633 patients in Padova. Eur J Endocrinol. 2013; №169:773–784. 140. Myhre A.G., Aarsetøy H., Undlien D.E., Hovdenak N., Aksnes L., Husebye E.S. High frequency of coeliac diseaseamongpatients with autoimmune adrenocortical failure. Scand J Gastroenterol. 2003; №38:511–515. 141. Betterle C., Lazzarotto F., Spadaccino A.C., Basso D., Plebani M., Pedini B., Chiarelli S., Albergoni M. Celiac disease in North Italian patients with autoimmune Addison’s disease. Eur J Endocrinol. 2006; №154:275–279. 142. Arlt W., Society for Endocrinology Clinical Committee. Society for endocrinology endocrine emergency guidance: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients. Endocr Connect. 2016; №5 (5):G1-G3. 143. Penna-Martinez M., Meyer G., Wolff A.B., Skinningsrud B., Betterle C., Falorni A., Ollier W., Undlien D., Husebye E., Pearce S., Mitchell A.L., Badenhoop K. 64 Vitamin D status and pathway genes in five European autoimmune Addison's disease cohorts. Eur J Endocrinol. 2021; №184(3):373-381. 144. Reato G., Morlin L., Chen S., Furmaniak J., Smith B.R., Masiero S., Albergoni M.P., Cervato S., Zanchetta R., Betterle C. Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab. 2011; №96:E1255–E1261. 145. Winqvist O., Gustafsson J., Rorsman F., Karlsson F.A., Kämpe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison’s disease. J Clin Invest. 1993; №92:2377–2385. 146. Falorni A., Brozzetti A., Aglietti M.C., Esposito R., Minarelli V., Morelli S., Sbroma Tomaro E., Marzotti S. Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency. Clin Endocrinol (Oxf). 2012; №77:453– 458. 147. Betterle C., Dal Pra C., Mantero F., Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002;23(3):327- 364. doi:10.1210/er.23.3.327. 148. Bratland E., Husebye E.S. Cellular immunity and immunopathology in autoimmune Addison’s disease. Mol Cell Endocrinol. 2011; №336 (1-2):180-190. 149. Yamamoto T. Comorbid Latent Adrenal Insufficiency with Autoimmune Thyroid Disease. Eur Thyroid J. 2015; №4 (3):201-206. 150. Yamamoto T. History of Stress-related Health Changes: A Cue to Pursue a Diagnosis of Latent Primary Adrenal Insufficiency. Intern Med. 2014; №53 (3):183-188. doi:10.2169/internalmedicine.53.1156. 151. Cohen J., Venkatesh B. Relative adrenal insufficiency in the intensive care population; background and critical appraisal of the evidence. Anaesth Intensive Care. 2010; №38 (3):425-36. 152. Keevil B.G. Novel liquid chromatography tandem mass spectrometry (LC-MS/MS) methods for measuring steroids. Best Pract Res Clin Endocrinol Metab. 2013; №27:663– 674. 153. Prough R.A., Clark B.J., Klinge C.M. Novel mechanisms for DHEA action. Journal of Molecular Endocrinology. 2016; № 3:R139–R155. 154. Christiansen J.J., Bruun J.M., Christiansen J.S., Jørgensen J.O., Gravholt C.H. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle 65 function, and bone metabolism: a randomized trial. Eur J Endocrinol. 2011; №165:293– 300. 155. Mallappa A., Sinaii N., Kumar P., Whitaker M.J., Daley L.A., Digweed D., Eckland D.J., Van Ryzin C., Nieman L.K., Arlt W., Ross R.J., Merke D.P. A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2015; №100:1137– 1145. 156. Johannsson G., Nilsson A.G., Bergthorsdottir R., Burman P., Dahlqvist P., Ekman B., Engström B.E., Olsson T., Ragnarsson O., Ryberg M., Wahlberg J., Biller B.M., Monson J.P., Stewart P.M., Lennernäs H., Skrtic S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012; №97:473–481. 157. Quinkler M., Beuschlein F., Hahner S., Meyer G., Schöfl C., Stalla G.K. Adrenal cortical insufficiency-a life threatening illness with multiple etiologies. Dtsch Arztebl Int. 2013; №110 (51-52):882-8. 158. ClinicalTrials.gov [Internet]: Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia. URL: https://clinicaltrials.gov/ct2/show/study/NCT02716818. 159. Langenheim J., Ventz M., Hinz A., Quinkler M. Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm Metab Res. 2013; №45 (2):96-101. 160. Oksnes M., Björnsdottir S., Isaksson M., Methlie P., Carlsen S., Nilsen R.M., Broman J.E., Triebner K., Kämpe O., Hulting A.L., Bensing S., Husebye E.S., Løvås K. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison’s disease: a randomized clinical trial. J Clin Endocrinol Metab. 2014; №99:1665–1674. 161. Gagliardi L., Nenke M.A., Thynne T.R., von der Borch J., Rankin W.A., Henley D.E., Sorbello J., Inder W.J., Torpy D.J. Continuous subcutaneous hydrocortisone infusion therapy in Addison’s disease: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2014; №99:4149–4157. 162. Russell G.M., Durant C., Ataya A., Papastathi C., Bhake R., Woltersdorf W., Lightman S. Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014; №81:289–293. 66 163. Gan E.H., MacArthur K., Mitchell A.L., Hughes B.A., Perros P., Ball S.G., James R.A., Quinton R., Chen S., Furmaniak J., Arlt W., Pearce S.H. Residual adrenal function in autoimmune Addison’s disease: improvement after tetracosactide (ACTH1–24) treatment. J Clin Endocrinol Metab. 2014; №99:111–118. 164. Pearce S.H., Mitchell A.L., Bennett S., King P., Chandran S., Nag S., Chen S., Smith B.R., Isaacs J.D., Vaidya B. Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison’s disease. J Clin Endocrinol Metab. 2012; №97:E1927– E1932. 165. Napier C., Gan E.H., Mitchell A.L., Gilligan L.C., Rees D.A., Moran C., Chatterjee K., Vaidya B., James R.A., Mamoojee Y., Ashwell S., Arlt W., Pearce S.H.S. Residual Adrenal Function in Autoimmune Addison’s Disease—Effect of Dual Therapy With Rituximab and Depot Tetracosactide. J Clin Endocrinol Metab. 2020; №105 (4):e1250–e1259. 166. Ruiz-Babot G., Hadjidemetriou I., King P.J. Guasti L. New directions for the treatment of adrenal insufficiency. Front. Endocrinol. 2015; №6:70.